MX2016004088A - Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo. - Google Patents

Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.

Info

Publication number
MX2016004088A
MX2016004088A MX2016004088A MX2016004088A MX2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A MX 2016004088 A MX2016004088 A MX 2016004088A
Authority
MX
Mexico
Prior art keywords
somatostatin receptor
agonistic activity
compound
medicinal use
somatostatin
Prior art date
Application number
MX2016004088A
Other languages
English (en)
Inventor
Takuya Nishio
Tetsuya Sekiguchi
Akiharu Ishida
Takeshi Matsushita
Yasuyuki Okabe
Tatsuya Komagata
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2016004088A publication Critical patent/MX2016004088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona un agonista del receptor de somatostatina subtipo 2. Un compuesto descrito representado. por la fórmula general (I) en donde todos los símbolos tienen las mismas definiciones como se describió en la descripción; una sal del mismo, un N-óxido del mismo o un solvato del mismo, o un profármaco del anterior es un compuesto de bajo peso molecular que tiene fuerte actividad agonista del receptor de somatostatina subtipo 2, y por lo tanto se puede administrar de una manera simple, tiene una alta estabilidad y tiene baja toxicidad. Por lo tanto, el presente compuesto es útil para la profilaxis y/o terapia de enfermedades relacionadas con somatostatina, tales como acromegalia y obstrucción gastrointestinal.
MX2016004088A 2013-09-30 2014-09-29 Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo. MX2016004088A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013205027 2013-09-30
JP2013268902 2013-12-26
PCT/JP2014/075794 WO2015046482A1 (ja) 2013-09-30 2014-09-29 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
MX2016004088A true MX2016004088A (es) 2016-06-06

Family

ID=52743606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004088A MX2016004088A (es) 2013-09-30 2014-09-29 Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.

Country Status (21)

Country Link
US (1) US9643951B2 (es)
EP (1) EP3053916B1 (es)
JP (1) JP6380402B2 (es)
KR (1) KR20160062023A (es)
CN (1) CN105593221B (es)
AU (1) AU2014325078B2 (es)
BR (1) BR112016007078A2 (es)
CA (1) CA2925651A1 (es)
DK (1) DK3053916T3 (es)
ES (1) ES2716151T3 (es)
HK (1) HK1223356A1 (es)
HU (1) HUE043374T2 (es)
IL (1) IL244813A0 (es)
MX (1) MX2016004088A (es)
PH (1) PH12016500573B1 (es)
PL (1) PL3053916T3 (es)
PT (1) PT3053916T (es)
RU (1) RU2666352C2 (es)
SG (1) SG11201602477YA (es)
TW (1) TWI628175B (es)
WO (1) WO2015046482A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000692A8 (pt) * 2016-07-14 2022-03-03 Crinetics Pharmaceuticals Inc Moduladores de somatostatina e usos destes
RU2019124888A (ru) * 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
UA127346C2 (uk) 2017-03-16 2023-07-26 Крінетікс Фармасьютікалс, Інк. Модулятори соматостатину та їх застосування
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
HUE059184T2 (hu) 2018-01-17 2022-10-28 Crinetics Pharmaceuticals Inc Szomatosztatin modulátorok elõállításának folyamata
US11608335B2 (en) 2018-02-12 2023-03-21 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019240246A1 (ja) * 2018-06-15 2019-12-19 小野薬品工業株式会社 ピペリジノール誘導体の新規な塩および新規結晶形
EP3853218A4 (en) 2018-09-18 2022-02-16 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES THEREOF
TW202115008A (zh) 2019-08-14 2021-04-16 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
AU2021341936A1 (en) 2020-09-09 2023-05-25 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
IL305011A (en) 2021-02-17 2023-10-01 Crinetics Pharmaceuticals Inc Crystal forms of a somatostatin modulator
CN116789674A (zh) * 2022-08-24 2023-09-22 杭州高光制药有限公司 Nlrp3炎性小体抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) * 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
NZ508066A (en) 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMIN DERIVATIVES
CO5261501A1 (es) 1999-11-10 2003-03-31 Takeda Pharmaceutical Derivados de acido pirazol-propionico y sus composiciones farmaceuticas
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CN101258152A (zh) 2005-07-04 2008-09-03 阿斯利康(瑞典)有限公司 作为pde4抑制剂用于治疗炎症和免疫疾病的吡啶并嘧啶衍生物
TW200726767A (en) 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
JP2009530276A (ja) * 2006-03-13 2009-08-27 メルク エンド カムパニー インコーポレーテッド ソマトスタチンアゴニスト
EP2054385A2 (en) 2006-08-15 2009-05-06 F. Hoffmann-Roche AG Phenyl, pyridine and quinoline derivatives
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

Also Published As

Publication number Publication date
US9643951B2 (en) 2017-05-09
EP3053916A4 (en) 2017-03-08
RU2016111659A3 (es) 2018-03-20
CN105593221A (zh) 2016-05-18
BR112016007078A2 (pt) 2017-12-12
AU2014325078B2 (en) 2018-10-25
RU2016111659A (ru) 2017-11-13
EP3053916B1 (en) 2019-01-30
PT3053916T (pt) 2019-03-26
EP3053916A1 (en) 2016-08-10
TWI628175B (zh) 2018-07-01
PH12016500573A1 (en) 2016-07-04
CA2925651A1 (en) 2015-04-02
US20160311794A1 (en) 2016-10-27
RU2666352C2 (ru) 2018-09-07
CN105593221B (zh) 2017-09-22
AU2014325078A1 (en) 2016-04-21
SG11201602477YA (en) 2016-05-30
KR20160062023A (ko) 2016-06-01
JPWO2015046482A1 (ja) 2017-03-09
PH12016500573B1 (en) 2016-07-04
HK1223356A1 (zh) 2017-07-28
DK3053916T3 (en) 2019-04-15
HUE043374T2 (hu) 2019-08-28
IL244813A0 (en) 2016-05-31
WO2015046482A1 (ja) 2015-04-02
PL3053916T3 (pl) 2019-06-28
TW201602092A (zh) 2016-01-16
ES2716151T3 (es) 2019-06-10
JP6380402B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
PH12016500573A1 (en) Compound having somatostatin agonistic activity and pharmaceutical uses thereof
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12017502363A1 (en) Brk inhibitory compound
PH12016500170A1 (en) Formulation of syk inhibitors
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12017501255A1 (en) Tricyclic spiro compound
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
NZ716840A (en) Combination formulation of two antiviral compounds
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MA34064B1 (fr) Compose heterocyclique
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12018500378A1 (en) Novel annelated phenoxyacetamides
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
PH12018501709A1 (en) Naphthridinedione derivatives
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MY185061A (en) Trpv1 antagonists including dihydroxy substituent and uses thereof
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.